| TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma SE Josefsson, K Beiske, YN Blaker, MS Førsund, H Holte, B Østenstad, ... Cancer immunology research 7 (3), 355-362, 2019 | 105 | 2019 |
| A TCR-based chimeric antigen receptor E Walseng, H Köksal, IM Sektioglu, A Fåne, G Skorstad, G Kvalheim, ... Scientific reports 7 (1), 10713, 2017 | 100 | 2017 |
| Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma H Köksal, P Dillard, SE Josefsson, SM Maggadottir, S Pollmann, A Fåne, ... Blood advances 3 (8), 1230-1243, 2019 | 49 | 2019 |
| Treating osteosarcoma with CAR T cells H Köksal, E Müller, EM Inderberg, Ø Bruland, S Wälchli Scandinavian Journal of Immunology 89 (3), e12741, 2019 | 45 | 2019 |
| A spheroid killing assay by CAR T cells P Dillard, H Köksal, EM Inderberg, S Wälchli JoVE (Journal of Visualized Experiments), e58785, 2018 | 24 | 2018 |
| Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy P Dillard, H Köksal, SM Maggadottir, A Winge-Main, S Pollmann, ... Molecular Therapy 29 (3), 1199-1213, 2021 | 20 | 2021 |
| TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. Cancer Immunol. Res. 2019; 7: 355–362. doi: 10.1158/2326-6066 SE Josefsson, K Beiske, YN Blaker, MS Førsund, H Holte, B Østenstad, ... CIR-18-0351.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 14 | |
| ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma N Mensali, H Köksal, S Joaquina, P Wernhoff, NP Casey, P Romecin, ... Nature Communications 14 (1), 3375, 2023 | 11 | 2023 |
| Combinatorial CAR design improves target restriction H Köksal, P Dillard, A Juzeniene, G Kvalheim, EB Smeland, JH Myklebust, ... Journal of Biological Chemistry 296, 2021 | 9 | 2021 |
| “Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms N Mensali, P Dillard, A Fayzullin, H Köksal, G Gaudernack, G Kvalheim, ... The FASEB Journal 35 (9), e21750, 2021 | 8 | 2021 |
| Chimeric antigen receptor preparation from hybridoma to T-cell expression H Köksal, E Baken, DJ Warren, GÅ Løset, EM Inderberg, S Wälchli Antibody Therapeutics 2 (2), 56-63, 2019 | 8 | 2019 |
| Colorectal cysts as a validating tool for CAR therapy P Dillard, M Lie, E Baken, VH Lobert, E Benard, H Köksal, EM Inderberg, ... BMC biotechnology 20 (1), 1-9, 2020 | 5 | 2020 |
| Efficient chimeric antigen receptor (CAR) targeting of a central epitope of CD22 NP Casey, CH Klee, A Fåne, B Caulier, A Graczyk-Jarzynka, M Krawczyk, ... Journal of Biological Chemistry, 104883, 2023 | 1 | 2023 |
| Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable? H Köksal, S Wälchli Translational Cancer Research 6, 3, 2017 | 1 | 2017 |
| Two chimeric antigen receptors specifically binding cd19 and igkappa G Kvalheim, E Smeland, EM Inderberg, S Wälchli, H Holte, JH Myklebust, ... US Patent App. 17/258,238, 2022 | | 2022 |
| Chimeric antigen receptors S Wälchli, E Walseng, EM Inderberg, H Köksal US Patent App. 16/753,948, 2020 | | 2020 |
| Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition H Köksal, P Dillard, SM Maggadóttir, G Kvalheim, EB Smeland, ... Cancer Research 79 (13_Supplement), 2318-2318, 2019 | | 2019 |
| Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma P Dillard, H Köksal, S Josefsson, SM Maggadottir, S Pollmann, A Fåne, ... Cancer Research 79 (13_Supplement), 1422-1422, 2019 | | 2019 |
| Abstract A035: Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition H Köksal, P Dillard, SM Maggadóttir, G Kvalheim, EB Smeland, ... Cancer Immunology Research 7 (2_Supplement), A035-A035, 2019 | | 2019 |
| Targeting lymphoma with CD37CAR: A pre-clinical study S Walchli, IM Sektioglu, H Köksal, SE Josefsson, A Faane, K Huse, ... Annals of Oncology 28, xi5, 2017 | | 2017 |
